Significance of Early-Stage Planning in Commercial ADC Success

Effective early-stage planning is foundational to the long-term success of Antibody Drug Conjugate (ADC) programs. However, in today’s development environment, planning must extend beyond discovery and preclinical strategy to ensure seamless progression through clinical development, process validation (PPQ), and commercial manufacturing.

At Bora Biologics, we approach early-stage development with a commercial lens from the outset. Our teams prioritize manufacturability, scalability, and regulatory alignment early in the lifecycle to ensure that ADC programs are positioned for efficient advancement into late-stage clinical supply and licensure-stage production.

With a recently completed $30 million expansion at our FDA-approved U.S. facility in San Diego, Bora Biologics now operates validated 2,000L single-use GMP manufacturing suites designed to support commercial-scale biologics production. Importantly, the facility was engineered with built-in infrastructure to accommodate future 5,000L configurations, enabling rapid scale implementation as program demand evolves.

By integrating commercial manufacturing considerations early—process robustness, material flow, analytical readiness, and GMP execution discipline—we reduce downstream risk during technology transfer, scale-up, and PPQ campaigns. This structured, forward-looking approach ensures continuity from development through commercial launch, minimizing execution risk and accelerating time-to-market.

In ADC manufacturing, technical complexity requires close integration across process development, analytical sciences, quality, and GMP operations. Our cross-functional model ensures that early decisions align with commercial manufacturing realities, supporting inspection-ready execution at every stage.

Early planning is not simply about reducing risk—it is about building a scalable, inspection-ready foundation for long-term commercial success.

Future Trends in ADCs and the Demand for Commercial-Scale Infrastructure

The global ADC market continues to expand, with projections indicating growth from USD 11.84 billion in 2024 to USD 25.38 billion by 2033, reflecting sustained demand for targeted oncology therapies. This expansion is supported by a robust development pipeline: more than 530 ADC programs are currently in development globally, with approximately 47% in discovery or preclinical stages.

As this pipeline matures, a growing proportion of ADC candidates will advance into late-stage clinical trials and commercial manufacturing. This shift increases demand for CDMO partners with validated, scalable, and inspection-ready GMP infrastructure capable of supporting licensure-stage production.

Recent industry investments—including significant expansions in ADC manufacturing capacity across North America and Europe—underscore the increasing need for commercial-scale bioconjugation and biologics manufacturing capabilities. Sponsors are prioritizing partners that are already operating at scale, rather than preparing for it.

At Bora Biologics, our San Diego site is fully operational at 2,000L single-use scale and designed to support scalable expansion to 5,000L. This infrastructure allows sponsors to transition from clinical manufacturing to PPQ and commercial supply within a facility purpose-built for sustained commercial cadence.

As regulatory expectations intensify and supply chain resilience becomes a strategic priority, U.S.-based FDA-approved manufacturing infrastructure has become a critical factor in ADC development strategy. Sponsors are increasingly evaluating long-term manufacturing partnerships that support dual sourcing, geographic risk mitigation, and scalable capacity aligned with commercial forecasts.

Looking ahead, the ADC field will continue evolving through improved linker technologies, expanded target indications, and increasing adoption as first-line therapies in oncology. As more programs approach licensure, execution discipline, scalable GMP capacity, and inspection readiness will define successful manufacturing partnerships.

Conclusion
Bora Biologics is positioned to support the next generation of ADC programs with validated commercial-scale infrastructure, integrated GMP expertise, and a forward-engineered manufacturing platform.

With operational 2,000L single-use suites, facility design enabling 5,000L scalability, and an FDA-approved U.S. manufacturing environment, we provide sponsors with the confidence of inspection-ready, licensure-stage execution.

As the ADC pipeline advances toward commercialization, success will depend not only on innovation but on disciplined manufacturing strategy and scalable infrastructure. Bora Biologics is committed to delivering both—enabling sponsors to progress from development through commercial launch with operational certainty and long-term manufacturing continuity.

Bring Your ADC Program to Commercial Scale with Confidence

Schedule a Technical Consultation

Validated 2,000L GMP suites. Infrastructure engineered for 5,000L scalability. FDA-approved U.S. facility.